EN PL
CASE REPORT
Felty’s syndrome – report of three cases
 
More details
Hide details
 
Online publication date: 2010-04-09
 
 
Reumatologia 2010;48(1):66-70
 
KEYWORDS
ABSTRACT
Felty’s syndrome (FS) is a rare complication of rheumatoid arthritis (RA). FS comprises a triad of signs: RA, neutropenia and (obligatory) splenomegaly. Severe articular and extra-articular manifestations of RA are distinctive for FS. Proposed mechanisms of neutropenia in FS include: maturation arrest of granulocyte precursors, inhibition of G-CSF by cytokines, antibodies directed against granulocytes and increased granulocyte margination. The main problems connected with neutropenia are recurrent bacterial infections involving mostly the respiratory tract and skin. Hyperviscosity syndrome is very rare in FS. In differential diagnosis of neutropenia in RA drug toxicity, viral infections and haematological diseases (first of all T-cell large granular lymphocyte leukaemia – T-LGL) should be excluded. Treatment of FS is based on disease-modifying drugs (DMARD). Sometimes granulocyte colony-stimulating factors (G-CSF and GM-CSF) or splenectomy are applied. We describe three cases of patients with FS treated in our department.
 
REFERENCES (17)
1.
Geza P, Balist MD, Peter V. Felty’s syndrome. Best Pract Res Clin Rheum 2004; 18: 631-645.  .
 
2.
Prochorec-Sobieszek M, Wagner T, Maryniak R. Zespół Fel- ty’ego i białaczka z dużych ziarnistych limfocytów T – podobieństwa i różnice. Reumatologia 2007; 45: 85-91.  .
 
3.
Turesson C, Schaid DJ, Weyand CM. The impact of HLA-DRB1 genes on extra-articular disease manifestations in rheumatoid arthritis. Arthritis Res Ther 2005; 7: 1386-1393.  .
 
4.
Conkley G, Brooks D, Iqbal M, et al. Major histocompatility complex haplotypic associations in Felty’s syndrome and large granular lymphocyte syndrome are secondary to allelic association with HLA-DRB1 *0401. Rheumatology 2000; 39: 393-398.  .
 
5.
Lekharaju V, Chattopadhyay C. Efficacy of rituximab in Felty’s syndrome. Ann Rheum Dis 2008; 67: 1352.  .
 
6.
Breedveld FC, Fibbe WE, Hermans J, et al. Factors influencing the incidence of infections in Felty’s syndrome. Arch Intern Med 1987; 915-920.  .
 
7.
Hellmich B, Pinals RS, Loughran TP, Sullivan KE. New clues to accrue on neutropenia in rheumatoid arthritis. Clin Immunol 2005; 117: 1-5.  .
 
8.
Visser K, Katchamart W, Loza E, et al. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis 2009; 68: 1086-1093.  .
 
9.
Mahevas M, Audia S, De Lastours V, et al. Neutropenia in Felty’s syndrome successfully treated with hydroxychloroquine. Haematologica 2007; 92: e78-e79. .
 
10.
Ishikawa K, Tsukada Y, Tamura S, et al. Salazopiridine – induced remission of Felty’s syndrome along with significant reduction in neutrophil – bound immunoglobulin G. J Rheumatol 2003; 30: 404-406. .
 
11.
Almoallim H, Klinkhoff A. Longterm outcome of Felty’s syndrome with intramuscular golg: case reports and recommendations for management. J Rheumatol 2005; 32: 20-26. .
 
12.
Wassenberg S, Herborn G, Rau R. Methotrexate treatment in Felty’s syndrome. Br J Rheum 1998; 37: 908-911. .
 
13.
Talip F, Walker N, Khan W, et al. Treatment of Felty’s syndrome with leflunomide. J Rheumatol 2001; 28: 868-870. .
 
14.
Zakzook SI, Yunus MB, Mulconrey DS. Hyperviscosity syndrome in rheumatoid arthritis with Felty’s syndrome: case report and review of the literature. Clin Rheumatol 2002; 21: 82-85. .
 
15.
Ghavami A, Genevay S, Fulpius T, et al. Etanercept in treatment of Felty’s syndrome. Ann Rheum Dis 2005; 64: 1090-1091. .
 
16.
Salama A, Schneider U, Dörner T. Beneficial response to rituximab in a patient with haemolysis and refractory Felty syndrome. Ann Rheum Dis 2008; 67: 894-895. .
 
17.
Smedby KE, Askling J, Mariette X, et al. Autoimmune and inflammatory disorders and risk of malignant lymphomas-an update. J Inter Med 2008; 6: 514-527.
 
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
eISSN:2084-9834
ISSN:0034-6233
Journals System - logo
Scroll to top